 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Prior to synthesis we will analyse the sequence ordered by you to determine any abnormalities that might occur during the synthesis procedure and discuss this with you.
| Cat. No. | Peptides | Qty | Purity | Formulation | QC |
| PEP-SMR010 | <10mers | >10mg | >80% | lyophilized | - |
| PEP-SMP010 | <10mers | >10mg | >95% | lyophilized | HPLC/MALDI-TOF |
| PEP-LMR010 | 10-30mers | >10mg | >80% | lyophilized | - |
| PEP-LMP010 | 10-30mers | >10mg | >95% | lyophilized | HPLC/MALDI-TOF |
| Cat.No. | Product Description | Format |
| EPI-1310012 | 100 x 13mers | Peptide spotted on nitrocellulose |
| EPI-1320012 | 200 x 13mers | Peptide spotted on nitrocellulose |
